Search
Spotlight
In-person and virtual events just for HCPs
In-person and virtual events just for HCPs
Specialty
View More
Breast Cancer
Lung Cancer
Gastrointestinal Cancer
Genitourinary Cancers
Ovarian Cancer
Prostate Cancer
Melanoma & Skin Cancer
MCL
MPN
CAR T-cell Therapy
Chronic Lymphocytic Leukemia
Gynecologic Oncology
Hematologic Oncology
Immuno-Oncology
Multiple Myeloma
Urothelial Cancer
Breast Cancer
Lung Cancer
Gastrointestinal Cancer
Genitourinary Cancers
Ovarian Cancer
Prostate Cancer
Melanoma & Skin Cancer
MCL
MPN
CAR T-cell Therapy
Chronic Lymphocytic Leukemia
Gynecologic Oncology
Hematologic Oncology
Immuno-Oncology
Multiple Myeloma
Urothelial Cancer
News
OncClub
All Oncology News
Pipeline Report
OncClub
All Oncology News
Pipeline Report
Media
Insights
Medical World News
MedNews Week
OncChats
OncLive News Network®
OncLive TV
Peer Exchange
Podcasts
Rapid Readouts
The Talk
Insights
Medical World News
MedNews Week
OncChats
OncLive News Network®
OncLive TV
Peer Exchange
Podcasts
Rapid Readouts
The Talk
Conferences
Conference Coverage
Conference Listing
Conference Coverage
Conference Listing
Events
Giants of Cancer Care
PER Events
Scientific Interchanges
State of the Science Summit / IPC
Webinars
Giants of Cancer Care
PER Events
Scientific Interchanges
State of the Science Summit / IPC
Webinars
Partners
Publications
Oncology Live®
Oncology Fellows
Supplements and Featured Publications
All Publications
Oncology Live®
Oncology Fellows
Supplements and Featured Publications
All Publications
CME/CE
Resources
Interactive Tools
Learning Modules
Sponsored
Interactive Tools
Learning Modules
Sponsored
Biomarker Consortium
Subscribe
Search
Spotlight
In-person and virtual events just for HCPs
Specialty
See All >
Breast Cancer
Lung Cancer
Gastrointestinal Cancer
Genitourinary Cancers
Ovarian Cancer
Prostate Cancer
Melanoma & Skin Cancer
MCL
MPN
CAR T-cell Therapy
Chronic Lymphocytic Leukemia
Gynecologic Oncology
Hematologic Oncology
Immuno-Oncology
Multiple Myeloma
Urothelial Cancer
Management of Drug-Induced Interstitial Lung Disease - Episode 4
Use of Antibody Drug Conjugates and Potential for ILD
June 30, 2020
Tiffany A. Traina, MD, Memorial Sloan Kettering Cancer Center
,
Hope S. Rugo, MD, FASCO, UCSF Helen Diller Family Comprehensive Cancer Center
,
Axel Grothey, MD, West Cancer Center, University of Tennessee
,
Jarushka Naidoo, MBBCh, Sidney Kimmel Cancer Center, Johns Hopkins
,
Tanios Bekaii-Saab, MD, FACP, Mayo Clinic
EP. 1: Antibody Drug Conjugates and Interstitial Lung Disease Risk
EP. 2: Risks for Developing ILD and Personal Experience
EP. 3: Changes in Cancer Treatment and Management of ILD
Now Viewing
EP. 4: Use of Antibody Drug Conjugates and Potential for ILD
EP. 5: Rate and Class Effect of ILD with Antibody Drug Conjugates
EP. 6: CDK 4/6 Inhibitors and Identifying ILD in Patients
EP. 7: Managing Patient Symptoms and Clinician Education
EP. 8: Drug-Induced ILD and Rate of Occurrence in GI Cancer Trials
EP. 9: Patient Factors for Developing ILD and Personal Experience
EP. 10: Patient Management upon Developing ILD and Education
EP. 11: Potential Risk of Drug-Induced Interstitial Lung Disease
EP. 12: Personal Experience with Drug-Induced ILD
EP. 13: Rate of ILD and Monitoring Parameters
EP. 14: Identifying Drug-Induced ILD
EP. 15: Patient Management and Educational Tools for ILD
EP. 16: Role of Antibody Drug Conjugates and Personal Experience
EP. 17: Risks for Developing ILD in Gastrointestinal Cancer Studies
EP. 18: Risk of ILD as a Class Effect and Identifying ILD
EP. 19: Changes in Treatment Goals due to Drug Induced ILD
EP. 20: Management of Patients Who Develop ILD
EP. 21: Educational Tools for Possible Drug-Induced ILD